New research advances understanding and treatment of neurodegenerative diseases. Studies reveal that familial Alzheimer’s mutations impair neurotrophic exosome secretion by brain immune cells, linking to disease progression. Remynd NV reports positive phase IIa clinical trial data showing its novel compound reduces pathological tau and improves cognition in Alzheimer’s patients. Nanonewron secured a $2.5 million NIH grant to support TNF-α inhibitor development targeting Alzheimer’s and related conditions. Additionally, loss-of-function variants in the lipid transporter gene ABCA7 are confirmed as significant Alzheimer’s risk factors.